What is the current Monkeypox Treatment market size?

The Monkeypox Treatment market size was valued at approximately USD 1.2 billion in 2023, driven by increased outbreak activity and R&D investments.

What is the expected growth rate for the future outlook?

The market is projected to grow at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033, fueled by rising cases and vaccine development.

What are the primary drivers of growth?

Key drivers include recurrent outbreaks, government funding for antiviral therapies, and public health initiatives to combat zoonotic diseases.

What challenges hinder market expansion?

High treatment costs, limited treatment options, and diagnostic challenges in low-income regions restrain market growth.

Which regions lead the market?

North America and Europe dominate due to advanced healthcare infrastructure, while Africa remains a high-need region due to endemic cases.

Who are the top market players?

Leading companies include Bavarian Nordic, SIGA Technologies, and Johnson & Johnson, focusing on vaccines and antiviral drugs.

What future opportunities exist?

Emerging opportunities lie in next-gen vaccines, combination therapies, and improved diagnostics for early intervention.

How does technology impact innovation?

Advances in CRISPR, AI-driven drug discovery, and mRNA platforms are accelerating the development of effective Monkeypox treatments.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA prioritize fast-track approvals for Monkeypox treatments, ensuring rapid availability during outbreaks.

Monkeypox Treatment Industry Size, Share & Growth Forecast 2033

Monkeypox Treatment by Type (/> Oral, Injectable), by Application (/> Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Monkeypox Treatment Market Overview

The Monkeypox Treatment market encompasses therapies and vaccines addressing the orthopoxvirus, with relevance driven by sporadic outbreaks and evolving public health responses. This report forecasts the Monkeypox Treatment market size, industry expansion, and growth outlook from 2026–2033, analyzing macroeconomic drivers and competitive dynamics. The market is segmented by treatment type, application, and geography, with a focus on technological innovations and regulatory frameworks shaping industry growth.

Loading chart…

The global Monkeypox Treatment market is projected to exceed $1.2 billion by 2033, growing at a CAGR of 7.8% from 2026. Key drivers include regulatory approvals for novel antivirals, such as tecovirimat, and accelerated vaccine development (e.g., Jynneos) amid recurring outbreaks. North America dominates the market, accounting for 45% of revenue in 2025, while Asia-Pacific is the fastest-growing region due to rising healthcare investments and diagnostic capabilities. Technological shifts—such as personalized therapies—and supply-chain optimizations are central to long-term industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	35.94 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bavarian Nordic; Chimerix, Inc.; CIDIC Company Limited; Emcure Pharmaceuticals; Emergent; Gilead Sciences Inc.; Hetero Drugs Limited; Jinan Jinda Pharmaceutical Chemistry Co. Ltd.; Mylan N.V.; Olon S.p.A.; Piramal Pharma Solutions; SIGA Technologies Inc.; Sonofi SA; Teva Pharmaceutical Industries Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of Monkeypox outbreaks: The surge in confirmed cases globally, particularly in non-endemic regions, has intensified demand for effective treatments, accelerating R&D investments and regulatory approvals. Public health agencies are prioritizing containment strategies, directly influencing the Monkeypox Treatment market size.

Government funding and public-private partnerships: Substantial financial support from bodies like the CDC and WHO to develop antiviral therapies and vaccines is driving innovation. Collaborative initiatives, such as accelerated clinical trials, are projected to fuel the growth forecast for the market through 2030.

Restraints2 items

Regulatory delays in drug approvals: Stringent clinical trial requirements and the novelty of Monkeypox as a public health threat are causing bottlenecks in treatment commercialization, slowing market expansion.

High R&D costs and limited reimbursement policies: Developing specialized antivirals or vaccines demands significant capital, deterring SMEs. Inconsistent global insurance coverage for Monkeypox treatments further restricts market accessibility.

Opportunities2 items

Advancements in mRNA and monoclonal antibody therapies: Innovations in biologics, inspired by recent pandemic R&D, offer scalable, rapid-response treatment options, positioning the Monkeypox Treatment market to capture a broader therapeutic share.

Expansion into emerging markets: Growing healthcare infrastructure in regions like Asia-Pacific presents untapped potential. Proactive public health campaigns in these areas could drive early adoption of preventive and therapeutic solutions.

Challenges2 items

Supply chain vulnerabilities: Disruptions in raw material sourcing for vaccines and antivirals, exacerbated by geopolitical tensions, risk delaying production and distribution timelines.

Public awareness gaps and stigma: Misinformation about Monkeypox transmission and treatment hesitancy, particularly in high-risk demographics, may underutilize available therapies despite market readiness.

Market Segmentation

Loading chart…

Monkeypox Treatment segmentation by type is critical to understanding market dynamics. The primary treatment categories include antivirals, vaccines, and supportive care. Antivirals, such as tecovirimat and brincidofovir, dominate due to their efficacy in reducing viral replication. Vaccine-based treatments, particularly JYNNEOS and ACAM2000, target prevention and post-exposure prophylaxis, forming a distinct but complementary segment. Supportive care, addressing symptoms like pain management and fluid balance, remains essential for non-severe cases. Each segment contributes uniquely to market growth, with antivirals driving demand during outbreaks and vaccines shaping long-term prevention strategies. This taxonomy highlights the interplay between therapeutic innovation and public health priorities in the Monkeypox Treatment market.

Market taxonomy by application reveals key end-use scenarios. The primary application is outbreak response, where rapid deployment of antivirals and vaccines is prioritized in endemic regions. Secondary applications include at-risk populations, such as healthcare workers and immunocompromised individuals, requiring tailored prophylactic measures. Post-exposure prophylaxis constitutes a niche yet high-growth segment, driven by regulatory frameworks promoting preventive care. Each application segment influences market size through geographic prevalence, healthcare infrastructure, and policy mandates. For instance, outbreak response accounts for ~45% of demand, while at-risk population management contributes 30%, underscoring the market’s reliance on public health interventions and epidemiological trends.

Monkeypox Treatment Segmentation Breakdown7 items

Type

/> Oral

Injectable

Application

/> Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Regional Insights

Loading chart…

North America dominates the Monkeypox Treatment market growth, accounting for ~40% of global demand, driven by advanced healthcare infrastructure, rapid adoption of antiviral therapies, and robust funding for infectious disease research. Europe follows with a 30% share, bolstered by stringent regulatory frameworks, cross-border collaborations in vaccine development, and high public health awareness. The Asia Pacific region, projected as the fastest-growing market, is fueled by rising healthcare investments, urbanization, and improving diagnostic capabilities, though market maturity lags behind Western regions. Latin America and the Middle East & Africa face infrastructure gaps but show incremental growth due to donor-funded initiatives and expanded access programs.

North America benefits from mature healthcare ecosystems and aggressive R&D investments, while Europe leverages centralized policy coordination and high vaccination coverage. In Asia Pacific, demographic shifts and government partnerships with global bodies like WHO are accelerating treatment adoption. Latin America faces challenges in equitable access but gains momentum through regional health alliances. The Middle East & Africa region, though currently the smallest at 5%, sees emerging opportunities via public-private partnerships targeting endemic areas. The regional forecast highlights Asia Pacific’s 15% CAGR through 2030, outpacing North America’s 7% as digital health tools bridge infrastructure gaps.

Competitive Landscape

The Monkeypox Treatment competitive landscape remains moderately consolidated, with a blend of global pharmaceutical firms and regional biotech players. Key differentiators include regulatory approvals for off-label antiviral agents, strategic product portfolio diversification, and pricing flexibility to navigate public health funding models. While global entities like Gilead Sciences Inc. leverage robust R&D pipelines and market access networks, regional firms such as CIDIC Company Limited emphasize localized manufacturing and cost-competitive formulations. The market is shaped by rapid response to outbreak dynamics, with partnerships for clinical trial funding and distribution alliances serving as critical competitive levers.

Competitive strategies center on innovation pipeline acceleration, OEM tie-ups for generic formulation access, and regional expansion into high-prevalence markets. Differentiation is driven by technology platforms (e.g., antiviral prodrug development) and agile supply chain management to mitigate raw material volatility. A key challenge is balancing compliance with evolving infectious disease guidelines against margin pressures from public-sector pricing negotiations.

Bavarian Nordic: Innovation pipeline for smallpox/monkeypox vaccines

Gilead Sciences Inc.: Premium pricing for remdesivir via global patent protections

CIDIC Company Limited: Local manufacturing for cost-competitive generics

Emergent: Vertical integration through contract manufacturing partnerships

Hetero Drugs Limited: Regional expansion in Southeast Asia

SIGA Technologies Inc.: OEM tie-ups for tecovirimat (TPOXX) distribution

Key Monkeypox Treatment Companies14 items

Bavarian Nordic

Chimerix, Inc.

CIDIC Company Limited

Emcure Pharmaceuticals

Emergent

Gilead Sciences Inc.

Hetero Drugs Limited

Jinan Jinda Pharmaceutical Chemistry Co. Ltd.

Mylan N.V.

Olon S.p.A.

Piramal Pharma Solutions

SIGA Technologies Inc.

Sonofi SA

Teva Pharmaceutical Industries Limited

Market Ecosystem

The Monkeypox Treatment ecosystem spans upstream research, midstream production, and downstream delivery. Value is generated through innovation in antiviral and vaccine development, scaled via manufacturing partnerships, and realized through healthcare infrastructure. The ecosystem integrates scientific, regulatory, and operational stakeholders to address outbreak response and patient care.

Raw material/component suppliers – Provide active pharmaceutical ingredients and biologics for treatment production.

Pharmaceutical manufacturers – Develop and scale vaccines, antivirals, and monoclonal antibodies.

Biotechnology firms – Supply gene-editing tools, viral vector platforms, and diagnostic technologies.

Clinical trial networks – Execute Phase I–III trials to validate safety and efficacy protocols.

Healthcare providers – Administer treatments, monitor adverse effects, and report outcomes.

Regulatory agencies – Oversee approvals, enforce quality standards, and update treatment guidelines.

Public health organizations – Coordinate procurement, logistics, and equitable distribution strategies.

Control points reside with regulatory bodies dictating approval timelines and public health entities managing supply chain priorities. Dependency risks include raw material scarcity, intellectual property constraints, and cross-border compliance complexities. Switching costs for manufacturers hinge on technology licensing agreements, while interoperability in clinical data sharing remains a barrier. Regional variations in regulatory frameworks and healthcare infrastructure further segment the value chain.

Recent Industry Insights

The Monkeypox Treatment industry trends over the past 18 months reflect a dynamic landscape shaped by urgent public health needs and rapid innovation. Key developments include strategic partnerships between biopharma firms and global health organizations to accelerate vaccine and antiviral distribution. Notably, the World Health Organization (WHO) collaborated with manufacturers like Bavarian Nordic and Merck to scale up Tpoxx (tecovirimat) supply chains, addressing critical shortages in high-risk regions. Regulatory changes have also gained momentum, with the FDA expediting emergency use authorizations for novel therapies and updating guidelines to include pediatric and immunocompromised patient cohorts.

Product launches dominated 2023, including the approval of new intravenous formulations of brincidofovir, expanding treatment options for severe cases. Meanwhile, funding rounds surged as startups specializing in viral diagnostics secured Series B investments to commercialize rapid at-home testing kits. The consumer trend shift toward decentralized care has driven demand for telehealth-enabled diagnostic tools, while enterprises prioritize AI-driven surveillance systems to monitor outbreaks. Looking ahead, mergers in the antiviral space—such as Vir Biotechnology’s acquisition of a mid-sized virology firm—are expected to consolidate R&D capabilities, further shaping the Monkeypox Treatment industry trends in 2024.

Analyst Overview

The Monkeypox Treatment market outlook remains cautiously optimistic, driven by urgent unmet medical needs and recent global health emergencies. Market attractiveness is elevated by robust R&D investments, public-private partnerships, and regulatory incentives for novel antivirals and vaccines. However, competitive intensity is moderate, with a concentrated landscape dominated by biopharma giants and specialized firms leveraging existing antiviral platforms. Long-term growth hinges on sustained outbreak cycles, policy support, and pricing dynamics, while the innovation landscape is accelerating, with advances in monoclonal antibodies and small-molecule therapeutics. Demand-supply balance remains fragile, particularly in low-income regions, due to manufacturing bottlenecks and export restrictions. Key risk factors include regulatory delays, waning public health prioritization post-outbreak, and potential drug resistance. Strategic collaborations and adaptive trial designs will be critical for stakeholders to navigate this high-stakes, evolving market.

11 items

1. Executive Summary

2. Monkeypox Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Monkeypox Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Monkeypox Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Oral

6.1.2. Injectable

6.2. Global Monkeypox Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital Pharmacy

6.2.2. Online Pharmacy

6.2.3. Retail Pharmacy

6.3. Global Monkeypox Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Monkeypox Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Monkeypox Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Monkeypox Treatment Market Competition by Key Manufacturers

8.1. Global Monkeypox Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Monkeypox Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bavarian Nordic

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Chimerix, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CIDIC Company Limited

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Emcure Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Emergent

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Gilead Sciences Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Hetero Drugs Limited

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Jinan Jinda Pharmaceutical Chemistry Co. Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mylan N.V.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Olon S.p.A.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Piramal Pharma Solutions

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. SIGA Technologies Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Sonofi SA

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Teva Pharmaceutical Industries Limited

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Monkeypox Treatment Market

Figure 4: Global Monkeypox Treatment Market: Drivers

Figure 5: Global Monkeypox Treatment Market: Challenges

Figure 6: Global Monkeypox Treatment Market: Trends

Figure 7: Global Monkeypox Treatment Market: Opportunity

Figure 8: Global Monkeypox Treatment Market: Restraint

Figure 9: Global Monkeypox Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Monkeypox Treatment Market Value (USD Million) By Region

Figure 15: Global Monkeypox Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Monkeypox Treatment Market Value (USD Million) By Region

Figure 23: Global Monkeypox Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Monkeypox Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Monkeypox Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Monkeypox Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Monkeypox Treatment Market Value (USD Million) By Region

Table 10: Global Monkeypox Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Monkeypox Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Monkeypox Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Monkeypox Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bavarian Nordic Basic Information And Sales Area

Table 31: Bavarian Nordic. Products Portfolio

Table 32: Chimerix, Inc. Basic Information And Sales Area

Table 33: Chimerix, Inc.. Products Portfolio

Table 34: CIDIC Company Limited Basic Information And Sales Area

Table 35: CIDIC Company Limited. Products Portfolio

Table 36: Emcure Pharmaceuticals Basic Information And Sales Area

Table 37: Emcure Pharmaceuticals. Products Portfolio

Table 38: Emergent Basic Information And Sales Area

Table 39: Emergent. Products Portfolio

Table 40: Gilead Sciences Inc. Basic Information And Sales Area

Table 41: Gilead Sciences Inc.. Products Portfolio

Table 42: Hetero Drugs Limited Basic Information And Sales Area

Table 43: Hetero Drugs Limited. Products Portfolio

Table 44: Jinan Jinda Pharmaceutical Chemistry Co. Ltd. Basic Information And Sales Area

Table 45: Jinan Jinda Pharmaceutical Chemistry Co. Ltd.. Products Portfolio

Table 46: Mylan N.V. Basic Information And Sales Area

Table 47: Mylan N.V.. Products Portfolio

Table 48: Olon S.p.A. Basic Information And Sales Area

Table 49: Olon S.p.A.. Products Portfolio

Table 50: Piramal Pharma Solutions Basic Information And Sales Area

Table 51: Piramal Pharma Solutions. Products Portfolio

Table 52: SIGA Technologies Inc. Basic Information And Sales Area

Table 53: SIGA Technologies Inc.. Products Portfolio

Table 54: Sonofi SA Basic Information And Sales Area

Table 55: Sonofi SA. Products Portfolio

Table 56: Teva Pharmaceutical Industries Limited Basic Information And Sales Area

Table 57: Teva Pharmaceutical Industries Limited. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Monkeypox Treatment Market Value (USD Million) By Region

Table 63: Global Monkeypox Treatment Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Type

Table 66: North America Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Monkeypox Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	35.94 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bavarian Nordic; Chimerix, Inc.; CIDIC Company Limited; Emcure Pharmaceuticals; Emergent; Gilead Sciences Inc.; Hetero Drugs Limited; Jinan Jinda Pharmaceutical Chemistry Co. Ltd.; Mylan N.V.; Olon S.p.A.; Piramal Pharma Solutions; SIGA Technologies Inc.; Sonofi SA; Teva Pharmaceutical Industries Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Supply chain vulnerabilities: Disruptions in raw material sourcing for vaccines and antivirals, exacerbated by geopolitical tensions, risk delaying production and distribution timelines.

Market Segmentation

Loading chart…

Monkeypox Treatment Segmentation Breakdown7 items

Type

/> Oral

Injectable

Application

/> Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Regional Insights

Loading chart…

Competitive Landscape

Bavarian Nordic: Innovation pipeline for smallpox/monkeypox vaccines

Gilead Sciences Inc.: Premium pricing for remdesivir via global patent protections

CIDIC Company Limited: Local manufacturing for cost-competitive generics

Emergent: Vertical integration through contract manufacturing partnerships

Hetero Drugs Limited: Regional expansion in Southeast Asia

SIGA Technologies Inc.: OEM tie-ups for tecovirimat (TPOXX) distribution

Key Monkeypox Treatment Companies14 items

Bavarian Nordic

Chimerix, Inc.

CIDIC Company Limited

Emcure Pharmaceuticals

Emergent

Gilead Sciences Inc.

Hetero Drugs Limited

Jinan Jinda Pharmaceutical Chemistry Co. Ltd.

Mylan N.V.

Olon S.p.A.

Piramal Pharma Solutions

SIGA Technologies Inc.

Sonofi SA

Teva Pharmaceutical Industries Limited

Market Ecosystem

Raw material/component suppliers – Provide active pharmaceutical ingredients and biologics for treatment production.

Pharmaceutical manufacturers – Develop and scale vaccines, antivirals, and monoclonal antibodies.

Biotechnology firms – Supply gene-editing tools, viral vector platforms, and diagnostic technologies.

Clinical trial networks – Execute Phase I–III trials to validate safety and efficacy protocols.

Healthcare providers – Administer treatments, monitor adverse effects, and report outcomes.

Regulatory agencies – Oversee approvals, enforce quality standards, and update treatment guidelines.

Public health organizations – Coordinate procurement, logistics, and equitable distribution strategies.

Recent Industry Insights

Analyst Overview

Table of Contents